The world is rapidly changing with numerous and frequent digital transformations. How can these be implemented and utilised effectively to ensure customer-centricity in the pharma sector?

How is generative AI being utilised in drug discovery to improve processes and secure higher-quality drugs?

The use of artificial intelligence is becoming increasingly common in life sciences R&D. In what areas can it be utilised in the most helpful manner?

Cloud-based tools like process analytical technology can be used to improve pharma manufacturing processes, speeding up quality assurance and time-to-market in a cost-effective manner

IPT speaks to Michael Ruch at TaBlitz about the use of AI in tablet design, why it’s effective and how it will develop in the future

Large language models can be useful in the pharmaceutical industry in order to streamline digital capabilities. However, steps must be taken in order to mitigate the phenomenon of AI hallucinations – incorrect and false data that can jeopardise a company’s data set

Pharma laboratories should be looking to innovative digital techniques such as data, AI and the cloud to aid drug discovery and research

AI, especially genAI, is becoming increasingly popular in the pharma and life sciences industries. How can companies use large language models – and more specifically, retrieval augmented generation architectures – to ensure AI-generated results are accurate?

Frailty should not be considered an inevitability, but the effects can be significant. How can technological innovations combat this?

While still in its infancy, it is estimated that both AR and VR will surpass 100 million users worldwide by 2027. In realising this trend, it is clear that organisations adopting AR/VR app development services to create immersive experiences for their users which may enable them to excel within the realm of healthcare

Ensuring a robust foundation of performance metrics to underpin a strategy is key to navigating the challenges and getting fit for growth. However, amid firefighting to overcome day-to-day challenges, knowing where to start in setting key performance indicators and finding the right ways to track, measure and analyse them to glean actionable insights can often be a minefield that is easily sidelined

In the UK, one in 50 adults is living with a chronic wound, leading to more than £8bn in healthcare costs in 2017/2018. However, these numbers are likely to be higher since the pandemic as a result of reduced care in 2020 and 2021, impacting patient outcomes. With a growing ageing population and the increasing prevalence of people with comorbidities, these costs are likely to continue to rise until new solutions can be implemented to improve current standard care and control